Key terms
About GH
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GH news
Apr 03
8:32am ET
Guardant Health to present data on epigenomics at 2024 AACR meeting
Apr 03
5:19am ET
Canaccord positive on Exact, Guardant after Freenome data
Apr 02
9:49am ET
Exact Sciences, Guardant rally after Freenome colorectal cancer test results
Mar 22
5:22pm ET
Guardant Health Revises Co-CEOs’ Compensation and Incentives
Mar 19
2:30am ET
Analysts’ Top Healthcare Picks: Compass Therapeutics (CMPX), Guardant Health (GH)
Mar 14
7:18am ET
Buy Rating Affirmed for Guardant Health Amid Strong Shield Test Prospects and Positive ECLIPSE Study Results
Mar 14
7:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Guardant Health (GH), Cue Health (HLTH) and Skye Bioscience (OtherSKYE)
Mar 13
5:03pm ET
Guardant Health’s ECLIPSE study data demonstrates efficacy of Shield blood test
Feb 27
5:25am ET
BTIG Keeps Their Buy Rating on Guardant Health (GH)
Feb 26
7:39am ET
Guardant Health price target lowered to $30 from $40 at Piper Sandler
Feb 26
7:16am ET
Scotiabank Keeps Their Buy Rating on Guardant Health (GH)
Feb 25
11:26pm ET
Buy Rating for Guardant Health Amid Strong Market Position and Promising Future Prospects
Feb 23
7:47am ET
Buy Rating Affirmed for Guardant Health Amid Growth and Upcoming Catalysts
Feb 23
7:46am ET
Guardant Health price target lowered to $37 from $44 at TD Cowen
Feb 23
7:33am ET
Piper Sandler Reaffirms Their Buy Rating on Guardant Health (GH)
Feb 23
7:32am ET
Stifel Nicolaus Remains a Buy on Guardant Health (GH)
Feb 23
6:25am ET
Guardant Health price target lowered to $35 from $38 at BofA
Feb 23
5:35am ET
Guardant Health price target lowered to $45 from $50 at Canaccord
Feb 23
5:17am ET
Buy Rating Affirmed for Guardant Health Amidst Conservative FY24 Guidance and Promising Growth Prospects
Feb 22
10:55pm ET
Guardant Health Buy Rating Affirmed Amidst Conservative Guidance and Undervalued Base Business
Feb 22
4:08pm ET
Guardant Health sees FY24 revenue $655M-$670M, consensus $669.36M
Feb 22
4:07pm ET
Guardant Health reports Q4 adjusted EPS (64c), consensus (87c)
Feb 20
8:41am ET
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), IQVIA Holdings (IQV) and Ascendis Pharma (ASND)
Feb 20
8:40am ET
Craig-Hallum Remains a Buy on Guardant Health (GH)
Jan 11
1:28am ET
Guardant Health Receives Buy Rating from Puneet Souda Amid Strong Quarterly Performance and Promising Regulatory Prospects
Jan 09
9:10am ET
Analysts Are Bullish on Top Healthcare Stocks: BioLife Solutions (BLFS), Dynavax (DVAX)
Jan 09
9:01am ET
Guardant Health price target lowered to $54 from $64 at Craig-Hallum
Jan 09
7:35am ET
Stifel Nicolaus Sticks to Its Buy Rating for Guardant Health (GH)
Jan 09
5:14am ET
Guardant Health Outperforms with Strong Q4 Results and Promising 2024 Projections: A Buy Rating
Jan 08
12:05pm ET
Guardant Health’s preliminary Q4 results well ahead of consensus, says Canaccord
Jan 08
9:28am ET
Guardant Health sees FY23 revenue $562M-$563M, consensus $555.18M
GH Financials
Key terms
Ad Feedback
GH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
